Presenter: Laura Sepp-Lorenzino, Ph.D. Intellia Therapeutics
Date: December 4th, 2020
At Intellia, we are building a full-spectrum, product-driven biotechnology company focused on our mission of developing and commercializing potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. On the in vivo side, our systemic lipid nanoparticle or LNP-based delivery system has the potential to unlock treatment of genetic diseases by selectively knocking out disease-causing genes, introducing targeted insertion of a functional gene or both. We are also focused on engineering T cell therapies to provide them with particular enhanced attributes that may enable them to more effectively treat oncological and immunological diseases. Our approach is designed to improve safety and efficacy by engineering cell therapies that are more precise, potent and persistent. The OTS webinar will focus on Intellia’s in vivo platform and pipeline, highlighting the paths to gRNA selection, preclinical pharmacology and the clinic.
Basics of CRISPR
How Intellia’s Technology Works
Tour of Intellia
Laura Sepp-Lorenzino, Ph.D.
CSO, Intellia Therapeutics
Dr. Laura Sepp-Lorenzino is Executive Vice President, Chief Scientific Officer at Intellia Therapeutics, a company developing curative genome editing treatments to positively transform the lives of people with genetic diseases. She oversees all drug research across in vivo and engineered cell therapy areas at Intellia. Previously, she was VP, Head Nucleic Acid Therapies at Vertex Pharmaceuticals and before that, VP, Entrepreneur-in-Residence at Alnylam, a leader in the development of RNAi Therapeutics. At Alnylam, Laura was responsible for the Hepatic Infectious Disease Strategic Therapeutic Area, championed Extra Hepatic siRNA Delivery internally, and via a number of collaborations, was active in licensing and partnering. Before joining Alnylam, she spent 14 years at Merck & Co., having most recently served as Executive Director and Department Head, RNA Therapeutics Discovery Biology. In this role, Laura was responsible for identification and optimization of siRNAs and delivery vehicles, advancement of preclinical candidates, and development of an siRNA-conjugate platform to expand the repertoire of tissues accessible to in vivo siRNA delivery. Prior to her work with RNAi, Laura led the Cancer Research Department at Merck West Point, where she managed oncology drug discovery and development. She began her career in academia, as an Assistant Lab Member and Assistant Attending Molecular Biologist at Memorial Sloan-Kettering Cancer Center. Laura received her Professional Degree in Biochemistry from the University of Buenos Aires, and her M.S. and Ph.D. in Biochemistry from New York University.